RxDoctor Payments Data

Kurt Anderson, DO

Family Medicine · Shepherd, MINPI 1235181629

Payments from drug & device makers

$5,864in general payments, 2019–2025

Across 331 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$831
  • AstraZeneca$697
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$691
  • AbbVie$463
  • Otsuka America Pharmaceutical, Inc.$372
  • Vanda Pharmaceuticals Inc.$281
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$5,83399%
  • Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,864 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$13,976
Medicare patients
44
Services billed
214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide120$130,801
JardianceEmpagliflozin48$66,779
TrulicityDulaglutide29$42,684
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$35,527
EliquisApixaban34$32,906
OzempicSemaglutide19$28,652
Alosetron Hcl12$9,182
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,675
Mesalamine13$8,673
Combivent RespimatIpratropium/Albuterol Sulfate11$8,475
Lurasidone Hcl18$6,463
Albuterol Sulfate HfaAlbuterol Sulfate157$5,612
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$4,141
Venlafaxine Hcl ErVenlafaxine Hcl49$2,591
Atorvastatin Calcium208$2,144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$831$173,484149 claims
Boehringer IngelheimJardiance, Combivent Respimat$99$75,25459 claims
GSKTrelegy Ellipta$210$35,52734 claims
PfizerEliquis$167$32,90634 claims
Novo NordiskOzempic$146$28,65219 claims
AstraZenecaBreztri Aerosphere$697$8,67512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Shepherd

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →